LL-37

LL-37, a human antimicrobial peptide (cathelicidin), is primarily being investigated for its role as a biomarker and therapeutic target rather than as a direct treatment. Current clinical research focuses on several key areas:

Periodontal Disease

Recent clinical trials have examined LL-37 levels as biomarkers in periodontal disease treatment. One completed study (NCT04404335) investigated the role of LL-37 alongside anti-inflammatory cytokines in periodontal therapy. Additional research has explored the relationship between vitamin D insufficiency, periodontitis, and LL-37 levels in diabetic patients, suggesting LL-37 may serve as a useful biomarker for monitoring periodontal health and treatment response.

Vitamin D-Related Studies

Multiple clinical trials have investigated the relationship between vitamin D supplementation and LL-37 levels:

• A completed study (NCT03923218) examined how smoking and vitamin D3 supplementation affect LL-37 levels
• Several trials explored vitamin D's effects in various populations, including smokers with and without HIV, though some were terminated or withdrawn

Emerging Research Areas

Skin Conditions: Laboratory research indicates LL-37's involvement in rosacea-like skin inflammation, with studies showing that certain compounds can suppress LL-37-generated inflammation through specific signaling pathways.

Cancer Research: Preliminary studies suggest LL-37 may inhibit osteosarcoma progression by suppressing cholesterol synthesis pathways, though this research remains in early laboratory stages.

Infectious Diseases: Research has examined LL-37's role in tuberculosis and other infections, particularly in relation to vitamin D status, though clinical applications remain investigational.

Current Limitations

The clinical evidence for LL-37 as a therapeutic intervention is limited. Most studies focus on LL-37 as a biomarker or examine how other treatments (particularly vitamin D supplementation) affect LL-37 levels. Direct therapeutic applications of LL-37 itself have not progressed to advanced clinical trials.

This information is for educational purposes only and does not constitute medical advice. Consult healthcare professionals for personalized treatment recommendations.